



12 October 2022  
EMA/825713/2022  
Human Medicines Division

## Overview of (invented) names reviewed in September 2022 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 10-13 October 2022

	NRG meeting 15-16 Feb 2022		NRG meeting 28-29 Apr 2022		NRG meeting 28-29 Jun 2022		NRG meeting 20-21 Sep 2022		NRG meeting 15-16 Nov 2022		2022 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	54	42	60	40	44	26	47	26			205	134
Justification for retention of (invented) name **	1	9	3	3	4	3	1	5			9	20

\*Includes invented names, INN+MAH/TM and re-use applications.

\*\*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



	NRG meeting 15-16 Feb 2022		NRG meeting 28-29 Apr 2022		NRG meeting 28-29 Jun 2022		NRG meeting 20-21 Sep 2022		NRG meeting 15-16 Nov 2022		2022 total	
	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed
Total number of objections raised	85	155	82	194	45	121	50	136			<b>262</b>	<b>606</b>
Similarity with other (invented) name	63	107	58	125	31	99	43	103			<b>195</b>	<b>434</b>
Conveys misleading therapeutic/pharmaceutical connotations	1	1	6	2	0	2	0	2			<b>7</b>	<b>7</b>
Misleading with respect to composition	0	0	2	0	1	0	0	0			<b>3</b>	<b>0</b>
Similarity with INN	7	29	6	23	10	5	3	8			<b>26</b>	<b>65</b>
Inclusion of INN stem	1	1	2	0	0	0	1	0			<b>4</b>	<b>1</b>
Unacceptable qualifiers	0	0	5	1	0	2	0	1			<b>5</b>	<b>4</b>
Conveys a promotional message	4	4	3	11	1	3	2	7			<b>10</b>	<b>25</b>
Appears offensive or has an inappropriate connotation	3	1	0	1	1	0	0	0			<b>4</b>	<b>2</b>
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	0	0	0	0			<b>0</b>	<b>0</b>
Similarity between name of prodrug and related active substance	0	0	0	0	0	0	0	0			<b>0</b>	<b>0</b>
Others	6	12	0	31	1	10	1	15			<b>8</b>	<b>68</b>

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.